Scientific Session
Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Robert Lafyatis, MD
University of Pittsburgh
Pittsburgh, PA, United States
Disclosure(s): Advarra/GSK: Advisor or Review Panel Member (Ongoing); Bain Capital: Consultant (Terminated, September 22, 2023); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Certa Therapeutics: Consultant (Ongoing); Corbus: Consultant (Terminated, August 1, 2022), Grant/Research Support (Terminated, August 1, 2022); EMD Serono: Consultant (Ongoing); Formation: Consultant (Terminated, July 1, 2022), Grant/Research Support (Terminated, July 1, 2022); Genentech: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Moderna: Grant/Research Support (Terminated, January 1, 2023); Morphic: Consultant (Ongoing); Pfizer: Consultant (Terminated, April 6, 2023), Grant/Research Support (Terminated, April 6, 2023); Regeneron: Grant/Research Support (Terminated, January 1, 2023); Third Rock Venture: Consultant (Ongoing); Thirona Bio: Consultant (Ongoing), Officer or Board Member (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Zag Bio: Consultant (Ongoing)